謝興邦

HP Hsieh 2謝興邦  特聘研究員兼所長
生技與藥物研究所
Email: hphsieh@nhri.edu.tw
Podcast:藥物研發上的小問題大解惑 上集  下集
實驗室網頁:https://www.hphsiehlab.com/

 

學歷

  • 美國紐約州立大學石溪分校化學博士 (1993)
  • 國立清華大學化學碩士 (1987)
  • 國立清華大學化學學士 (1985)

經歷

  • 國家衛生研究院生技與藥物研究所 特聘研究員兼所長 (2023/1~)
  • 中央研究院生醫轉譯研究中心 合聘研究員 (2023/1~)
  • 國立清華大學化學系 合聘教授 (2014/8~)
  • 國立陽明交通大學生物科技學系 合聘教授 (2017/8~)
  • 國家衛生研究院生技與藥物研究所 研究員 (2007/9~2022/12)
  • 嚴重特殊傳染性肺炎中央流行疫情指揮中心 研究發展組小組長 (2020/7~2023/4)
  • 中央研究院生醫轉譯研究中心 研究員兼副主任 (2020/1-2022/12)
  • 國家生技研究園區創服育成中心進駐諮詢委員會 審議委員(2018~2022)
  • 安邦生物科技公司 創辦人兼科學諮詢委員會(2021~)
  • 經濟部生技醫藥產業發展推動小組 生技產業白皮書審查委員(2010~)
  • 經濟部產業發展署上櫃評估審查 審查委員(2022~)
  • 經濟部中小及新創企業署「中小企業創新研究獎」 審議委員(2023~)
  • 國科會新竹科學園區「新興科技應用計畫」 審查委員(2022)
  • 國衛院「藥物化學加值創新研發中心」 創辦主持人(2018~2019)
  • 台灣生物產業發展協會 理事(2024~)
  • 中國化學會 理事 常務理事(2017~2020)/理事(2023~)
  • 國家衛生研究院生技與藥物研究所 副所長 (2015/4~2019/12)
  • 國家衛生研究院技轉及育成中心 代理主任 (2018/9~2019/3)
  • 國家衛生研究院學術發展處 處長 (2012/2~2014/10)
  • 國家衛生研究院技轉及育成中心 主任 (2009/3~2012/2)
  • 國家衛生研究院圖書館 主任 (2007/11~2009/3)
  • 國家衛生研究院智慧財產管理委員會 召集人(2015~2020)
  • 國立陽明大學研發成果管理委員會 審議委員(2011~2017)
  • 國家衛生研究院第三屆人體生物資料庫倫理委員會 審查委員(2017~2019)
  • 國家衛生研究院圖書委員會 召集人(2017~2018)
  • 科技部生科司傑出研究獎 審議委員(2020~)
  • 科技部生科司藥學學門 複審委員(2021~2022)
  • 科技部生科司中醫藥學門 複審委員(2020)
  • 科技部生科司藥理學門 複審委員(2017~2019) (2023~)
  • 科技部自然司國際合作小組 審議委員(2016~2018)
  • 科技部自然司化學學門 諮議委員(2014~2017)
  • 科技部自然司化學學門 複審委員(2010~2013)
  • 王民寧獎 評審委員(2014~)
  • 李天德獎 評審委員(2014~)
  • 國家衛生研究院生物技術與藥物研究組 副研究員 (2003/2~2007/9)
  • 國立清華大學化學系 兼任教授 (2008~2014)
  • 國家衛生研究院生物技術與藥物研究組 助研究員 (1998/5~2003/2)
  • 中央研究院生物化學所 博士後研究員 (1996~1997)
  • 美國麻薩諸塞州波士頓學院 研究專員 (1994~1995)
  • Scientific Reports (Nature Series) 國際期刊編輯委員(2017~)
  • Letters in Drug Design & Discovery (LDDD) 國際期刊編輯委員(2014~)
  • Drug Discoveries & Therapeutics (DD&T)國際期刊編輯委員(2011~)
  • International Grant Reviewer – PRELUDIUM 9 proposal, Poland波蘭國家計畫審查委員 (2015)
  • J. Med. Chem., Org. Lett., Eur. J. Med. Chem., Bioorg. Med. Chem. Lett., Bioorg. Med. Chem. Oncotarget, Syn. Commun, ChemMedChem, J Biomed Sci., J. Chinese. Chem. Soc.期刊之評審委員

研究興趣

新藥研發，藥物設計與合成，化學生物，天然物合成

研究成果

謝興邦教授實驗室主要是專注於從事抗癌、抗病毒及糖尿病等新藥研發工作。目前已發表125篇國際論文，其中有29篇發表在藥物化學領域頂尖期刊 — Journal of Medicinal Chemistry。此外亦取得62項國內外專利，並產出三項抗癌新穎候選藥物－『DBPR104』、『DBPR112』、『DBPR114』，其中『DBPR104』已在台灣完成臨床一期和二期臨床試驗；『DBPR112』目前正在台灣進行第一期臨床試驗；『DBPR114』於2017年7月和11月分別獲得美國和台灣IND(新藥臨床試驗)核准。已完成二項技術移轉分別給杏國新藥與安邦生技。

學術獎勵

  • 第68屆教育部學術獎 (2024)
  • 2024年台北生技獎『技轉合作獎』金獎 (2024)
  • 入選全球2%頂尖科學家「終身科學影響力排行榜（1960-2023）」(2024)
  • 美國國家發明家學院院士(NAI Fellow) (2023)
  • 入選全球2%頂尖科學家「終身科學影響力排行榜（1960-2022）」(2023)
  • 中國化學會化學技術獎章 (2023)
  • 國家新創獎(2022)
  • 入選全球2%頂尖科學家「終身科學影響力排行榜（1960-2021）」(2022)
  • 入選兩項全球2%頂尖科學家(「終身科學影響力排行榜（1960-2020）」和「 2020 年度科學影響力排行榜」) (2021)
  • DBPR114專屬授權朗齊生技 (2021)
  • DBPR112專屬授權安邦生技 (2020)
  • 國際生醫加速器合作計畫Pitch Day (第二名) (2019)
  • 科技部「沙克爾頓培育輔導人才計畫」(2019-2021)
  • 科技部未來科技突破獎 (2018)
  • Asian CORE Program (ACP) Lectureship Award (2018)
  • 科技部傑出研究獎 (2017-2019)
  • 科技部未來科技突破獎 (2017)
  • 第26屆王民寧獎 (2016)
  • 國家衛生研究院傑出學術成就獎 (2015)
  • 國際傑出發明家終身成就獎(2014)
  • 第二十屆東元獎 (2013)
  • 第十屆國家新創獎(2013)
  • 國際傑出發明家學術國光獎章 (2012)
  • 董大成博士癌症基礎醫學研究傑出獎 (2011)
  • 國科會傑出研究獎 (2010-2012)
  • 經濟部智慧財產局「國家發明創作獎」 (2010)
  • 永信李天德卓越醫藥科技獎 (2009)
  • 國家衛生研究院年輕學者學術成就獎 (2006)

專利申請與獲證

  1. Wang, H. C.; Hsieh, H. P.; Kuo, C. C.; Sun, Y. J.; Pao, Y. S.; Liao, K. J.; Shiau, Y. C. Novel compound, pharmaceutical composition comprising the same and method for treating cancer using the same, US 18/919,681, Oct. 18, 2024
  2. Hsieh, H. P.; Lee, K. H.; Lin, W. H.; Shih, C. “Heterocyclic Compounds as Kinase Inhibitors for Therapeutic Uses​”, ZL 2020 8 0024676.8, 29, 2024-April 9, 2040.
  3. Hsieh, H. P.; Lee, K. H.; Lin, W. H.; Shih, C. “Heterocyclic Compounds as Kinase Inhibitors for Therapeutic Uses​”, JP7568641B2, Oct. 16, 2024-April 9, 2040.
  4. Hsieh, H. P. “The Method of the Preparation of Fused Multicyclic Compounds”, US12012400, June 18, 2024- April 13, 2042.
  5. Hsieh, H. P. “The Method of the Preparation of Fused Multicyclic Compounds”, TWI844822, June 11, 2024-Feb. 17, 2042.
  6. Hsieh, H. P. “The Method of the Preparation of Fused Multicyclic Compounds”, AU2022201063, April 26, 2024-Feb. 17, 2042.
  7. Hsieh, H. P. “The Method of the Preparation of Fused Multicyclic Compounds”, JP7416842, Jan. 9, 2024- 18, 2042.
  8. Hsu, T. A.; Hsieh, H. P.; Chang, S.M. “Crystalline Forms of (s, e)-4-(Dimethylamino)-n-(3-(4-(2- hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base”, TWI809967, July 21, 2023-July 4, 2042.
  9. Tsou, L. K.; Niu, G. H.; Hsieh, H. P.; Zhang, M.; Wen Z. H.; Sung, P. J. “Briarane Compounds and Their Use “, US, Nov. 28, 2022.
  10. Hsieh, H. P.; Yen, W. C.; Wu, S. Y.; Li, M. C.; Lin, W. H.; Ke, Y. Y. “Inhibitors of TAM Receptors “, US Provision 63/399,404, Aug. 19, 2022.
  11. Hsieh, H. P.; Lee, K. H.; Lin, W. H.; Shih, C. “Heterocyclic Compounds as Kinase Inhibitors for Therapeutic Uses​”, TW I757722, Mar. 11, 2022-April 10, 2040.
  12. Hsieh, H. P.; Coumar, M. S.; Chao, Y. S. “Fused Multicyclic Compounds as Protein Kinase Inhibitors”, KR1718386B1, March 21, 2017-Sep. 22, 2029.
  13. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Lin, W. H; Chen, Y. R.; Chao, Y. S. “Fused Bicyclic and Tricyclic Pyrimidine Compounds as EGFR Kinase Inhibitors”, KR1703941B1, 7, 2017- -Nov. 9, 2029.
  14. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, IN279196B, Jan. 20, 2017-April 22, 2029.
  15. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, EP2276346B1, Nov. 23, 2016-April 22, 2029.
  16. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, KR1667822B1, Oct. 19, 2016-April 22, 2029.
  17. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, CA2722220C, June 7,2016-April 22, 2029.
  18. Hsieh, H. P.; Coumar, M. S.; Chao, Y. S. “做為蛋白質激酶抑制劑之稠合多環化合物”, 0, March 23, 2016-Sep. 22, 2029.
  19. Lin, C. C.; Chang, WHW; Uang, B. J.; Chang, J. Y.; Chen, J. C.; Hsieh, H. P. “組織蛋白酶Ｓ抑制劑”, TWI516479, Jan 11, 2016-Dec. 6, 2030.
  20. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, AU2009241469, Aug. 20,2015-April 22, 2029.
  21. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Lin, W. H; Chen, Y. R.; Chao, Y. S. “Fused Bicyclic and Tricyclic Pyrimidine Compounds as EGFR Kinase Inhibitors”, JP5781934, July 24, 2015-Nov. 9, 2029.
  22. Hsieh, H. P.; Coumar, M. S.; Chao, Y. S. “Fused Multicyclic Compounds as Protein Kinase Inhibitors”, US9006252, April 14, 2015-Mar. 24, 2032.
  23. Lin, C. C.; Chang, WHW; Uang, B. J.; Chang, J. Y.; Chen, J. C.; Hsieh, H. P. “Cathepsin S inhibitors”, US8895497, Nov. 25, 2014-Dec. 6, 2030.
  24. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “作為極光激酶抑制劑的稠合雙環嘧啶化合物”, 4, Oct. 29,2014-April 22, 2029.
  25. Hsieh, H. P.; Yeh, J. Y.; Hsu, T. A.; Shih, S. R.; Horng, J. T.; Chang S. Y.; Chao, Y. S. “化合物於製造治療病毒感染的藥物之用途”, TWI457121, Oct. 21, 2014-June 11, 2029.
  26. Hsieh, H. P.; Yeh, J. Y.; Hsu, T. A.; Chao, Y. S. “Quinoline Compounds and their Use for Treating Viral Infection”, US8710079, April 29, 2014-April 21, 2031.
  27. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, JP5502072, March 20, 2014-April 22, 2029.
  28. Hsieh, H. P.; Chang, J. Y.; Kuo, C. C.; Chao, Y. S. “治療癌症的醫藥組成物”, TWI415852, Nov. 21, 2013-June 11, 2029.
  29. Hsieh, H. P.; Yeh, J. Y.; Hsu, T. A.; Chao, Y. S. “喹啉化合物及其用以治療病毒性感染之用途”, TWI410245, Oct. 1, 2013-April 22, 2031.
  30. Hsieh, H. P.; Coumar, M. S.; Chao, Y. S. “Fused Multicyclic Compounds as Protein Kinase Inhibitors”, EP2331530, Aug. 21, 2013-Sep. 22, 2029.
  31. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Lin, W. H; Chen, Y. R.; Chao, Y. S. “Fused Bicyclic and Tricyclic Pyrimidine Compounds as EGFR Kinase Inhibitors”, US8507502, Aug. 13, 2013– 9, 2029.
  32. Hsieh, H. P.; Coumar, M. S.; Chao, Y. S. “做為蛋白質激酶抑制劑之稠合多環化合物”, TWI400242, July 1, 2013-Sep. 23, 2029.
  33. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Lin, W. H; Chen, Y. R.; Chao, Y. S. “作為酪胺酸激酶抑制劑之稠合雙環及多環嘧啶化合物”, TWI385174, Feb. 11, 2013-Nov. 9, 2029.
  34. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “作為極光激酶抑制劑之稠合雙環嘧啶化合物”, TWI363627, May 11, 2012-April 29, 2029.
  35. Jiaang, W. T; Chao, Y. S.; Hsieh, H. P. “吡咯啉啶化合物”, TWI362388, April 21, 2012-Aug. 25, 2026.
  36. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, US8138194, March 20, 2012-April 22, 2029.
  37. Hsieh, H. P.; Liou, J. P.; Chang, J. Y.; Chang, C. W. “Indole Compounds”, CA2437104, March 6, 2012-Aug 13, 2023.
  38. Hsieh, H. P.; Hsu, T. A.; Chao, Y. S.; Chou, Y. C.; Wang, S. T. “引藻萃取物”, TWI356705, Jan. 21, 2012-Oct. 1, 2028.
  39. Jiaang, W. T; Chen, X.; Wu, S. Y.; Chao, Y. S.; Hsieh, H. P.; “Pyrrolidine Compounds”, CA2559611, Jan. 17, 2012-Mar 9, 2025.
  40. Hsieh, H. P.; Chang, J. Y.; Kuo, C. C.; Chao, Y. S. “Coumarin Compounds and Their Use for Treating Cancer”, US8058427, November 15, 2011-June 10, 2029.
  41. Hsieh, H. P.; Hsu, T. A.; Chao, Y. S.; Chou, Y. C.; Wang, S. T. “Extracts from Chlorella” US8048426, 1, 2011-April 30, 2029.
  42. Hsieh, H. P.; Hsu, T. A.; Hwang, D. R. “抑制Ｃ型肝炎病毒感染之倍半帖內酯類化合物及其醫藥組成物”, TWI344959, July 11, 2011-April 1, 2024.
  43. Hsu, T. A.; Hsieh, H. P.; Chao, Y. S.; Chen, C. M.; Jan, J. T.; Liu, H. W., “抑制冠狀病毒之醫藥組合物”, TWI343808, June 21, 2011-May 28, 2024.
  44. Hsu, T. A.; Hsieh, H. P.; Chao, Y. S.; Chen, C. M.; Jan, J. T.; Liu, H. W., “抑制冠狀病毒之醫藥組合物”, TWI343809, June 21, 2011-May 28, 2024.
  45. Hsu, T. A.; Hsieh, H. P.; Chao, Y. S.; Chen, C. M.; Jan, J. T.; Liu, H. W., “抑制冠狀病毒之醫藥組合物”, TWI343810, June 21, 2011-May 28, 2024.
  46. Hsieh, H. P.; Liou, J. P.; Chang, J. Y.; Chang, C. W. “Indole Compounds as Inhibitors of Tubulin Polymerisation for the Treatment of Angiogenesis-related Disorders”, EP1506960, April. 6, 2011-Aug. 7, 2023.
  47. Hsieh, H. P; Mahindroo, N.; Hsu, T. A.; Huang, C. F.; Chen, X.; Chao, Y. S. “吲哚化合物”, 8, December 1, 2010 – December 11, 2024.
  48. Hsieh, H. P.; Tung, Y. S.; Liou, J. P.; Chang, J. Y.; Chao, Y. S. “Anti-Tumor Compounds”, 7, December 1, 2010 – December 15, 2025.
  49. Jiaang, W. T; Chen, X.; Wu, S. Y.; Chao, Y. S.; Hsieh, H. P.; “Pyrrolidine Compounds”, CN1942186, Oct. 06, 2010-Mar 9, 2025.
  50. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, CA2598788, Aug. 3, 2010-Aug. 27, 2027.
  51. Hsieh, H. P.; Hsu, T. A.; Chao, Y. S.; Chou, Y. C.; Wang, S. T. “Extracts from Chlorella”, Singapore, 152154, July 15, 2010-Oct. 8, 2028.
  52. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, US7741495, June 22, 2010 – August 31, 2027.
  53. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, 日本特許第4521428號, May 28, 2010 – August 31, 2027.
  54. Jiaang, W. T; Chen, X.; Wu, S. Y.; Chao, Y. S.; Hsieh, H. P.; “Pyrrolidine Compounds”, US7687504, Mar. 30, 2010-Mar 9, 2025.
  55. Hsieh, H. P.; Liou, J. P.; Chang, J. Y.; Chang, C. W. “Indole Compounds”, US7632955, December 15, 2009 – December 12, 2022.
  56. Hsieh, H. P.; Liou, J. P.; Chang, J. Y.; Chang, C. W. “芳香羰吲哚化合物”, TWI317634, December 1, 2009 – December 11, 2022.
  57. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “吲哚啉磺胺化合物”, TWI315304, October 1, 2009 – August 31, 2027.
  58. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, KR10-0916989, September 4, 2009 – August 31, 2027.
  59. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, AU2007214336, June 4, 2009 – August 31, 2027.
  60. Hsu, T. A.; Hsieh, H. P.; Chao, Y. S.; Chen, C. M.; Jan, J. T.; Liu, H. W. “Treatment of Coronavirus Infection”, US7544712, June 9, 2009 – May 28,
  61. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, GB2441396, May 13, 2009 – August 31, 2027.
  62. Hsieh, H. P.; Liou, J. P.; Chang, J. Y.; Chang, C. W. “Indole Compounds,” US7528165, May 5, 2009 – December 12, 2022.
  63. Hsieh, H. P; Mahindroo, N.; Hsu, T. A.; Huang, C. F.; Chen, X.; Chao, Y. S. “吲哚化合物”, TWI304066, December 12, 2008 – December 11, 2024.
  64. Hsieh, H. P.; Tung, Y. S.; Liou, J. P.; Chang, J. Y.; Chao, Y. S. “Anti-Tumor Compounds,” US7456289, November 25, 2008 – December 15, 2025.
  65. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, NZ561060, November 13, 2008 – August 31, 2027.
  66. Hsieh, H. P; Mahindroo, N.; Hsu, T. A.; Huang, C. F.; Chen, X.; Chao, Y. S. “Indole Compounds” , US7449478, November 11, 2008 – December 3, 2024.
  67. Jiaang, W. T; Chao, Y. S.; Hsieh, H. P. “Pyrrolidine Compounds”, US7425633, September 16, 2008 – August 28, 2026.
  68. Jiaang, W. T; Chen, X.; Wu, S. Y.; Chao, Y. S.; Hsieh, H. P. “咯啶化合物”, TWI299039, July 21, 2008 – March 9, 2025.
  69. Hsieh, H. P.; Tung, Y. S.; Liou, J. P. Chang, J. Y.; Chao, Y. S. “抗腫瘤化合物”, TWI296195, May 1, 2008 – December 27, 2025.
  70. Jiaang, W. T; Chen, X.; Wu, S. Y.; Hsieh, H. P.; Chao, Y. S. “Pyrrolidine Compounds”, KR7038951, April 12, 2008 – August 28, 2
  71. Hsu, T. A.; Hsieh, H. P.; Juan, L. J; Chang, S. Y.; Kuo, Y. H. “一種抗病毒之醫藥組成物”, TW I293248, February 11, 2008 – May 21, 2023.
  72. Hsieh, H. P.; Liou, J. P.; Chang, J. Y.; Chang, C. W. “Indole Compounds”, US6933316, August 23, 2005 – December 12, 2022.
  73. Burrows, C. J.; Hsieh, H. P. “Steroidal Polyamines”, US5610149, 1997.

 論文發表

2025

  1. Pao, Y. S.; Liao, K. J.; Shiau, Y. C.; Chao, M. H.; Li, M. C.; Lin, L. M.; Chang, H. H.; Yeh, H. W.; Chen, Y. J.; Chiu, Y. T.; Pan, M. Y. C.; Chang, Y. H.; Shen, S. Y.; Lin, S. Y.; Hui-Chun Cheng, H. C.; Lin, Y. C.; Sun, Y. J.*; Kuo, C. C.*; Hsieh, H. P. *; Wang, L. H. C.* “KIF2C Mediates Paclitaxel Resistance by Resolving Polyglutamylated Microtubules” Developmental Cell, 2024, accepted (co-corresponding author) (SCI: 10.7) (2/39, DEVELOPMENTAL BIOLOGY)
  2. Hsueh, W. Y.; Wu, Y. L; Weng, M. T.; Liu, S. Y.; Santavanond, J. P.; Liu, Y. C; Lin, C. I.; Lai, C. N.; Lu, Y. R.; Hsu, J. Y.; Gao, H. Y.; Lee, J. C.; Wei, S. C.; Lyu, P. C.; Poon, I. K. H.; Hsieh, H. P.*; Chiu, Y. H.* “Novel Naphthyridones Targeting Pannexin 1 for Colitis Management” Adv. Sci. 2025, 12, e2411538 (co-corresponding author) (SCI: 14.3) (19/231, CHEMISTRY, MULTIDISCIPLINARY)
  3. Tang, Y.-C.; Ou, J.-J.; Hsu, S.-C.; Huang, C.-H.; Lin, L.-M.; Chang, H.-H.; Wang, Y.-H.; Huang, Z.-T.,; Sun, M.; Liu, K.-J.; Hung, Y.-M.; Lai, C.-Y.; Shih, C.; Chen, C.-T.; Chang, J.-Y.; Hsieh, H.-P.; Jiaang, W.-T.*; Kuo, C.-C.* “Advancing Precision Therapy for Colorectal Cancer: Developing Clinical Indications for Multi-target Kinase Inhibitor BPR1J481 Using Patient-Derived Xenograft Models” Pharmacol. Res. 2025, 211, 107556 (SCI: 9.1) (13/354, P PHARMACOLOGY & PHARMACY)
  4. Tahiliani, H.; Dhayalan, A.; Li, M. C.; Hsieh, H. P.; Coumar, M. S.* “Aldehyde Dehydrogenases as Drug Targets for Cancer: SAR and Structural Biology Aspects for Inhibitor Design” Bioorg Chem. 2025, 154, article 108019. (SCI: 4.5)(7/58, CHEMISTRY, ORGANIC)

2024

  1. Shih, W. H.; Huang, H. L; HuangFu, W. C.; Lin, T. E.; Sung, T. Y.; Li, M. C.; Huang, G. L.; Chang, Y. W.; Yen, S. C.; Hsieh, H. P.; Hsu, K. C.*; Pan, S. L.* “Discovery of Novel TANK-Binding Kinase 1 (TBK1) Inhibitor against Pancreatic Ductal Adenocarcinoma” Int. J. Biol. Macromol. 2024, 283, article 137296.
  2. Lin, S. Y.; Chang, Y. C,; Tien, Y. W.; Kuo, Y. H.; Chang, H. F.; Ou, L. C.; Chen, Y. P.; Chang, K. H.; Hsu, Y. T.; Huang, Y. C.; Yang, C. M.; Law, P. Y.; Xi, J. H.; Tao, P. L.; Loh, H. H.; Yeh, T. K.; Zhuang,  H.; Hsieh, H. P.; Shih, C.; Chen, C. T.; Yeh, S. H.*; Ueng, S. H.* “DBPR116, a Prodrug of BPRMU191, in Combination with Naltrexone as a Safer Opioid Analgesic Than Morphine via Peripheral Administration” J. Med. Chem. 2024, 67, 19777-19790. (SCI: 6.9)(3/72, CHEMISTRY, MEDICINAL)
  3. Li, M. C.; Lai, Y. L.; Kuo, P. H.; Reddy, J. S.; Chen, C. M.; Manimala, J.; Wang, P. C.; Wu, M. S.; Chang, C. Y.; Yang, C. M.; Lin, C. Y.; Huang, Y. C.; Chiu, C. H.; Chang, L.; Lin, W. H.; Yeh, T. K.*; Yen, W. C.*; Hsieh, H. P.* “Discovery of Dual MER/AXL Kinase Inhibitors as Bifunctional Small Molecules for Inhibiting Tumor Growth and Enhancing Tumor Immune Microenvironment” J. Med. Chem. 2024, 67, 10906-10927. (co-corresponding author) (SCI: 6.9)(3/72, CHEMISTRY, MEDICINAL)
  4. Yang, I. H.; Kuan, C. Y.; Zhang, S. L.; Chen, Z. Y.; Li, C. H.; Liang, Y. J.; Kuo, W. T.; Chang, C. T.; Lin, J.; Hsieh, H. P.; Chang, J. Y.; Lin, F. H.* “Macrophage-mediated controlled release of cysteine protease inhibitor from PLGA-PEG/hydroxyapatite microspheres for targeting cathepsin S in Alzheimer’s disease” Eur Polymer J. 2024, 214, Article number 113151. (SCI: 5.8)(9/95, POLYMER SCIENCE)
  5. Lee, H. W.; Chen, S.J.; Tsai, K. J.; Hsu, K. S.; Chen, Y. F.; Chang, C. H.; Lin, H. H.; Hsueh, W. Y.; Hsieh, H. P.; Lee, Y. F.; Chiang, H. C.; Chang, J. Y.* “Targeting Cathepsin S Promotes Activation of OLF1-BDNF/TrkB Axis to Enhance Cognitive Function” J. Biomed. Sci. 2024, 31, 46. (SCI: 9.0) (30/205, CELL BIOLOGY) Times Cited: 1

2023

  1. Chen, C. M.; Lin, S. K.; Hsieh, C. T.; Reddy, J. S.; Teoh, Y. N.; Cheng, M. J.*; Hsieh, H. P.* “Influence of Ring Strain on the Formation of Rearrangement vs Cyclization Isotwistane Products in the Acyl Radical Reaction of Bicyclo[2.2.2]octanone” Org. Lett. 2023, 25, 7757-7762. (co-corresponding author) (SCI: 4.9)(4/58, CHEMISTRY, ORGANIC) (Selected as COVER STORY)

  2. Hsu, Y. T.; Chen, S. R.;Chang, Y. C.; Chang H. F.;Yeh, T. K.; Chuang, J. Y.; Loh, H. H.; Hsieh, H. P.; Ueng*, S. H.;Yeh, S. H.* “A Dual Nociceptin and Mu Opioid Receptor Agonist Exhibited Robust Antinociceptive Effect with Decreased Side Effects” Eur. J. Med. Chem. 2023, 258, article 115608 (SCI: 6.0) (8/72, CHEMISTRY, MEDICINAL)
  3. Li, M. C.; Coumar, M. S.; Lin, Y. S.; Huang, G. L.; Chen, C. H.; Lien, T. W.; Wu, Y. W.; Chen, Y. T.; Chen, C. P.; Huang, Y. C.; Yeh, K. C.; Yang, C. M.; Kalita, B.; Pan, S. L.; Hsu, T. A.; Yeh, T. K.; Chen, C. T.; Hsieh, H. P.* “Development of Fu ranopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer” J. Med. Chem. 2023, 66, 2566–2588. (corresponding author) (SCI: 6.9)(3/72, CHEMISTRY, MEDICINAL)

2022

  1. Kumari, M.; Lu, R. M.; Li, M. C.; Huang, J. L.; Hsu, F. F.; Ko, S. H.; Ke, F. Y.; Su, S. C.; Liang, K. H.; Yuan, J. P. Y.; Chiang, H. L.; Sun, C. P.; Lee, I. J.; Li, W. S.; Hsieh, H. P.; Tao, M. H.; Wu, H. C.* “A Critical Overview of Current Progress for COVID‑19: Development of Vaccines, Antiviral Drugs, and Therapeutic Antibodies” J. Biomed. Sci. 2022, 29, Article number 68. (SCI: 9.0) (30/205, CELL BIOLOGY) Times Cited: 116
  2. Chen, C. M.*; Hsieh, H. P.* “Recent Advances in Total Synthesis of Natural Products by Masked Ortho-benzoquinones” J. Chin. Chem. Soc. 2022, 69, 1210-1222. (co-corresponding author) (SCI:1.6) (153/231, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 3
  3. Liu, J. S.; Fang, W. K.; Yang, S. M.; Wu, M. C.; Chen, T. J.; Chen, C. M.; Lin, T. Y.; Liu, K. L.; Wu, C. M.; Chen, Y. C.; Chuu, C. P.; Wang, L. Y.; Hsieh, H. P.; Kung, H. J.; Wang, W. C.* “Natural Product Myricetin is a Pan-KDM4 Inhibitor which with Poly Lactic-co-glycolic Acid Formulation Effectively Targets Castration-resistant Prostate Cancer” J. Biomed. Sci. 2022, 29, Article number 29. (SCI: 9.0) (30/205, CELL BIOLOGY) Times Cited: 13
  4. Lee, R. K.; Li, T. N.; Chang, S. Y.; Chao, T. L.; Kuo, C. H.; Pan, M. Y.; Chiou, Y. T.; Liao, K. J.; Yang, Y.; Wu, Y. H.; Huang, C. H.; Juan, H. F.; Hsieh, H. P.; Wang, L. H.* “Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2” Int. J. Mol. Sci. 2022, 23, 4050. (SCI: 4.9) (68/231, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 17
  5. Lai, Y. L.; Wang, K. H.; Hsieh, H. P.; Yen, W. C.* “Novel FLT3/AURK Multikinase Inhibitor is Efficacious against Sorafenib-refractory and Sorafenib-resistant Hepatocellular Carcinoma” J. Biomed. Sci. 2022, 29, Article number 5. (SCI: 9.0) (30/205, CELL BIOLOGY) Times Cited: 9

2021

  1. Lee, K. H.; Yen, W. C.; Lin, W. H.; Wang, P. C.; Lai, Y. L.; Su, Y. C.; Chang, C. Y.; Wu, C. S.; Huang, Y. C.; Yang, C. M.; Chou, L. H.; Yeh, T. K.; Chen, C. T.; Shih, C.; Hsieh, H. P.* “Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model” J. Med. Chem. 2021, 64, 14477-14497. (corresponding author) (SCI: 6.9)(3/72, CHEMISTRY, MEDICINAL) Times Cited: 22
  2. Huang, C. Y.; Lin, S. Y.; Hsu, T. A.; Hsieh, H. P.*; Huang, M. H.* “Colloidal Assemblies Composed of Polymeric Micellar/Emulsified Systems Integrate Cancer Therapy Combining a Tumor- Associated Antigen Vaccine and Chemotherapeutic Regimens” Nanomaterials, 2021, 11, article 1844. (co-corresponding author) (SCI: 4.4)(70/231, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 1
  3. Li, M. C.; Lin, W. H.; Wang, P. C.; Su, Y. C.; Chen, P. Y.; Fan, C. M.; Chen, C. P.; Huang, C. L.; Chiu, C. H.; Chang, L.; Chen, C. T.; Yeh, T. K.; Hsieh, H. P.* “Design and Synthesis of Novel Orally Selective and Type II Pan-TRK Inhibitors to Overcome Mutations by Property-Driven Optimization” Eur. J. Med. Chem. 2021, 224, article 113673 (corresponding author) (SCI: 6.0) (8/72, CHEMISTRY, MEDICINAL) Times Cited: 12
  4. Reddy, J. S.; Chen, C. M.; Coumar, M. S.; Sun, H. Y.; Sun, N.; Hsieh, H. P.* “Development of a Robust Scale-up Synthetic Route for BPR1K871: A Clinical Candidate for the Treatment of Acute Myeloid Leukemia and Solid Tumors” Org. Process Res. Dev. 2021, 25, 817-830. (corresponding author) (SCI: 3.1)(12/58, CHEMISTRY, ORGANIC) Times Cited: 4
  5. Charles, M. R. C.; Li, M. C.; Hsieh, H. P.*; Coumar, M. S.* “Mimicking H3 Substrate Arginine in the Design of G9a Lysine Methyltransferase Inhibitors for Cancer Therapy: A Computational Study for Structure-Based Drug Design” ACS Omega 2021, 6, 6100-6111. (co-corresponding author) (SCI: 3.7)(86/231, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 5
  6. Huynh, T. H.; Lee, G. H.; Tanaka J.; Hsieh, H. P.; Tsou, L. K.; Zhang, M. M.; Kuo, T. J.; Wen, Z. H.; Lu, C. K.; Sung P. J.* “Chlorinated Briarane Diterpenoids from Octocoral Briareum stechei (Kükenthal, 1908)” Tetrahedron Lett. 2021, 69, 152976. (SCI: 1.5)(38/58, CHEMISTRY, ORGANIC) Times Cited: 3
  7. Chen, Y. Y.; Zhang, Y. L.; Lee, G. H.; Tsou, L. K.; Zhang, M. M.; Hsieh, H. P.; Chen, J. J.; Ko, C. Y.; Wen, Z. H.; Sung P. J.* “Briarenols W-Z: Chlorine-Containing Polyoxygenated Briaranes from Octocoral Briareum Stechei (Kükenthal, 1908)” Mar. Drugs 2021, 19, 77. (SCI: 4.9)(14/72, CHEMISTRY, MEDICINAL) Times Cited: 4
  8. Taweesak, P.; Thongaram, P.; Kraikruan, P.; Thanetchaiyakup, A.; Chuanopparat, N.; Hsieh, H. P.; Uang, B. J.; Ngernmeesri, P.* “One-Pot Synthesis of Dibenzo[b,f]oxepines and Total Synthesis of Bauhinoxepin C” J. Org. Chem. 2021, 86, 1955-1963. (SCI: 3.4) (10/58, CHEMISTRY, ORGANIC) Times Cited: 8
  9. Syed, S. B.; Lin, S. Y.; Arya, H.; Fu, I. H.; Yeh, T. K.; Charles, M. R. C.; Periyasamy, L.;Hsieh, H. P.*; Coumar, M. S.* “Overcoming Vincristine Resistance in Cancer: Computational Design and Discovery of Piperine Inspired P-glycoprotein Inhibitors” Chem. Biol. Drug Des. 2021, 97, 51-66. (co-corresponding author) (SCI: 3.2)(39/72, CHEMISTRY, MEDICINAL) Times Cited: 8

2020

  1. Li, M. C.; Hsieh, H. P.* “Tumor-agnostic Inhibitors in Oncology: A New Phase for Precision Medicine” J. Chin. Chem. Soc. 2021, 67, 2216-2224. (corresponding author) (SCI: 1.6) (SCI:1.6) (153/231, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 1
  2. Arya, H; Yadav, C. S.; Lin, S. Y.; Syed, S. B.; Charles, M. R. C.; Kannadasan, S.; Hsieh, H. P.; Singh, S. S.; Gajurel, P. R.; Coumar, M. S.* “Design of a Potent Anticancer Lead Inspired by Natural Products from Traditional Indian Medicine” J. Biomol. Struct. Dyn. 2020, 38, 3563-3577. (SCI: 2.7) (193/313, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 5
  3. Blay, V.*; Li, M. C.; Ho, S. P.; Stoller, M. L.; Hsieh, H. P.; Houston, D. R. “Design of Drug-like Hepsin Inhibitors against Prostate Cancer and Kidney Stones” Acta. Pharm. Sin B. 2020, 10, 1309-1320. (SCI: 14.8)(5/354, PHARMACOLOGY & PHARMACY) Times Cited: 9
  4. Lin, S. Y.; Chang, C. F.; Coumar, M. S.; Chen, P. Y.; Kuo, F. M.; Chen, C. H.; Li, M. C.; Lin, W. H.; Kuo, P. C.; Wang, S. Y.; Li, A. S.; Lin, C. Y.; Yang, C. M.; Yeh, T. K.; Song, J. S.; Hsu, J. T. A.; Hsieh, H. P.* “Drug-like Property Optimization: Discovery of Orally Bioavailable Quinazoline-Based Multi-Targeted Kinase Inhibitors” Bioorg Chem. 2020, 98, 103689. (corresponding author) (SCI: 4.5)(7/58, CHEMISTRY, ORGANIC) Times Cited: 6
  5. Lai, C. H.; Chen, R. Y.; Hsieh, H. P.; Tsai, S. J.; Chang, K. C.; Yen, C. J.; Huang, Y. C.; Liu, Y. W.; Lee, J. C.; Lai, Y. C.; Hung, L. Y.*; Lin, B. W.* “A Selective Aurora-A 5′-UTR siRNA Inhibits Tumor Growth and Metastasis” Cancer Lett. 2020, 472, 97-107. (SCI: 9.1)(33/322, ONCOLOGY) Times Cited: 12
  6. Charles, M. R. C.; Mahesh, A.; Lin, S. Y.; Hsieh, H. P.; Dhayalan, A.*; Coumar, M. S.* “Identification of Novel Quinoline Inhibitor for EHMT2/G9a through Virtual Screening” Biochimie. 2020, 168, 220-230. (SCI: 3.3)(149/313, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 10

2019

  1. Lin, S. Y.; Hsu Yung, C.; Peng, Y. H. ; Ke, Y. Y.; Lin, W. H.; Sun,H. Y.; Kuo, F. M.; Chen, P. Y.; Lien, T. W.; Chen, C. H.; Chu, C. Y.; Wang, S. Y.; Yeh, K. C.; Chen, C. P.; Hsu, J. TA; Wu, S. Y.; Yeh, T. K.; Chen, C. T.; Hsieh, H. P.* “Discovery of Clinical Candidate DBPR112, a Furanopyrimidine-based Epidermal Growth Factor Receptor Inhibitor for the Treatment of Non-Small Cell Lung Cancer” J. Med. Chem. 2019, 62, 10108-10123. (corresponding author) (SCI: 6.9)(3/72, CHEMISTRY, MEDICINAL) Times Cited: 21
  2. Tseng, P. H.; Sie, Z. L.; Liu, M. C.; Lin, H. S.; Yang, W. Y.; Lin, T. Y.; Hsieh, H. P.; Hung, S. C.; Cheng, C. L.; Wang, H. D.; Chang, H. H.*; Yuh, C. H.* “Identification of Two Novel Small Compounds that Inhibit Liver Cancer Formation in Zebrafish and Analysis of Their Conjugation to Nanodiamonds to Further Reduce Toxicity” Adv. Therapeutics 2019, 2, 1900105. (SCI: 3.7)(90/354,PHARMACOLOGY & PHARMACY) Times Cited: 9
  3. Lin, H. H.; Chen, S. J.; Shen, M. R.; Huang, Y. T.; Hsieh, H. P.; Lin, S. Y.; Lin, C. C.; Chang, W. W.; Chang, J. Y.* “Lysosomal Cysteine Protease Cathepsin S is Involved in Cancer Cell Motility by Regulating Store-Operated Ca2+ Entry” Biochim. Biophys. Acta. Mol. Cell Res. 2019, 1866, 118517. (SCI: 4.6)(74/313, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 17
  4. Quattrini, L.; Coviello, V.; Sartini, S.; Di Desidero, T.; Orlandi, P.; Ke, Y. Y.; Liu, K. L.; Hsieh, H. P.; Bocci, G.; La Motta, C.* “Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation” Sci. Rep. 2019, 9, 9943. (SCI: 3.8)(25/134, MULTIDISCIPLINARY SCIENCES) Times Cited: 6
  5. Ramya, C. C. M.; Hsieh, H. P.; Coumar, M. S.* “Delineating the Active Site Architecture of G9a Lysine Methyltransferase through Substrate and Inhibitor Binding Mode Analysis: A Molecular Dynamics Study” J. Biomol. Struct. Dyn. 2019, 37, 2581-2592. (SCI: 2.7) (193/313, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 10
  6. Charles, M. R. C.; Dhayalan, A.; Hsieh, H. P.; Coumar, M. S.* “Insights for the Design of Protein Lysine Methyltransferase G9a Inhibitors” Future Med. Chem. 2019, 11, 993-1014. (SCI: 3.2) (39/72, CHEMISTRY, MEDICINAL) Times Cited: 25

2018

  1. Chen, C. M.; Shiao, H. Y.; Uang, B. J.; Hsieh, H. P.* “Biomimetic Syntheses of (±)-Isopalhinine A, (±)-Palhinine A, and (±)-Palhinine D” Chem. Int. Ed. Engl. 2018, 57, 15572-15576. (corresponding author) (SCI: 16.1)(14/231, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 20 獲得德國蒂姆醫學出版社SYNFACTS主編蘇黎世聯邦理工學院Erick M. Carreira教授選為 “synfact of the month” 作專文介紹 (Synfacts, 2019, 15, 1)。榮獲第十五屆永信李天德醫藥科技獎之「傑出論文獎」。
  2. Ke, Y. Y.; Chang, C. P.; Lin, W. H.; Tsai, C. H.; Chiu, I. C.; Wang, W. P.; Wang, P. C.; Chen, P. Y.; Lin, W. H.; Chang, C. F.; Kuo, P. C.; Song, J. S.; Shih, C.; Hsieh, H. P.*; Chi, Y. H.* “Design and Synthesis of BPR1K653 Derivatives Targeting the Back Pocket of Aurora Kinases for Selective Isoform Inhibition” Eur. J. Med. Chem. 2018, 151, 533-545. (corresponding author) (SCI: 6)(7/60, CHEMISTRY, MEDICINAL) Times Cited: 9
  3. La Pietra, V.; Sartini, S.; Botta, L.; Antonelli, A.; Ferrari, S. M.; Fallahi, P.; Moriconi, A.; Coviello, V.; Quattrini, L.; Ke, Y. Y.; Hsieh, H. P.; Da Settimo, F.; Novellino, E.; La Motta, C.*; Marinelli, L.* “Challenging Clinically Unresponsive Medullary Thyroid Cancer: Discovery and Pharmacological Activity of Novel RET Inhibitors” Eur. J. Med. Chem. 2018, 150, 491-505. SCI: 6)(7/60, CHEMISTRY, MEDICINAL) Times Cited: 15

2017

  1. Syed S. B.; Arya, H.; Fu, I. H.; Yeh, T. K.; Periyasamy, L.; Hsieh, H.P.*; Coumar, M. S.* “Targeting P-glycoprotein: Investigation of Piperine Analogs for Overcoming Drug Resistance in Cancer”. Sci. Rep. 2017, 7, 7972. (corresponding author) (SCI:3.8)(22/73, MULTIDISCIPLINARY SCIENCES) Times Cited: 80
  2. Singh, V. K.; Chang, H. H.; Kuo, C. C.; Shiao, H. Y.; Hsieh, H. P.; Coumar, M. S.* “Drug Repurposing for Chronic Myeloid Leukemia: In Silico and In Vitro Investigation of DrugBank Database for Allosteric Bcr-Abl Inhibitors” J. Biomol. Struct. Dyn. 2017, 35, 1833-1848. (SCI: 5.235) (100/297, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 18

2016

  1. Chang Hsu, Y.; Selvaraj, C. M. ; Wang, W. C.; Shiao, H. Y.; Ke, Y. Y.; Lin, W. H.; Kuo, C. C.; Chang, C. W.; Kuo, F. M.; Chen, P. Y.; Wang, S. Y.; Li, A. S.; Chen, C. H.; Kuo, P. C.; Chen, C. P.; Wu, M. H.; Huang, C. L.; Yen, K. J.; Chang, Y. I.; Hsu, J. T.; Chen, C. T.; Yeh, T. K.; Song, J. S.; Shih, C.; Hsieh, H. P.* “Discovery of BPR1K871, a Quinazoline Based, Multi-kinase Inhibitor for the Treatment of AML and Solid Tumors: Rational Design, Synthesis, In Vitro and In Vivo Evaluation” Oncotarget, 2016, 7, 86239-86256. (corresponding author) Times Cited: 16
  2. Chang. C. F.; Lin, W. H.; Ke, Y. Y.; Lin, Y. S.; Wang, W. C.; Chen, C. H.; Kuo, P. C.; Hsu, J. T.; Uang, B. J.*; Hsieh, H. P.* “Discovery of Novel Inhibitors of Aurora Kinases with Indazole Scaffold: In Silico Fragment-based and Knowledge-based Drug Design” Eur. J. Med. Chem. 2016, 124, 186-199. (corresponding author) (SCI: 7.088)(5/63, CHEMISTRY, MEDICINAL) Times Cited: 12
  3. Sarvagalla, S.; Hsieh, H. P.; Coumar, M. S.* “Therapeutic Polymeric Nanoparticles and the Methods of Making and Using thereof: A Patent Evaluation of WO2015036792” Expert Opin. Ther. Pat. 2016, 26, 751-755. (SCI: 6.714)(6/63, CHEMISTRY, MEDICINAL) Times Cited: 2
  4. Sarvagalla, S.; Cheung, C. H. A.; Tsai, J. Y.; Hsieh, H. P.; Coumar, M. S.* “Disruption of Protein-protein Interactions: Hot Spot Detection, Structure-based Virtual Screening and In Vitro Testing for the Anti-cancer Drug Target Survivin. RSC Advances 2016, 6, 31947-31959. (SCI: 4.036)(75/179, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 24

2015

  1. Ke, Y. Y.; Singh, V. K.; Coumar, M. S.; Hsu, Y. C.; Wang, W. C.; Song, J. S.; Chen, C. H.; Lin, W. H.; Wu, S. H.; Hsu, J. T.; Shih, C.; Hsieh H. P.* “Homology Modeling of DFG-in FMS-like Tyrosine Kinase 3 (FLT3) and Structure-based Virtual Screening for Inhibitor Identification” Sci. Rep. 2015, 5, 11702. (corresponding author) (SCI:4.997)(19/74, MULTIDISCIPLINARY SCIENCES) Times Cited: 52
  2. Wu, C. H.; Wang, C. J.; Chang, C. P.; Cheng, Y. C.; Song, J. S.; Jan, J. J.; Chou, M. C.; Ke, Y. Y.; Ma, J.; Wong, Y. C.; Hsieh, T. C.; Tien, Y. C.; Gullen, E. A.; Lo, C. F.; Cheng, C.Y.; Liu, Y. W.; Sadani, A. A.;Tsai, C. H.; Hsieh, H. P.; Tsou, L. K.*; Shia, K. S.* “Function-Oriented Development of CXCR4 Antagonists as Selective Human Immunodeficiency Virus (HIV)-1 Entry Inhibitors” J. Med. Chem. 2015, 58, 1452-1465. (SCI: 8.039)(3/63, CHEMISTRY, MEDICINAL) Times Cited: 23
  3. Sarvagalla, S.; Singh, V. K.; Ke, Y. Y.; Shiao, H. Y.; Lin, W. H.; Hsieh, H. P.; Hsu, J. T.; Coumar, M. S.* “Identification of Ligand Efficient, Fragment-like Hits from an HTS Library: Structure-based Virtual Screening and Docking Investigations of 2H– and 3H-Pyrazolo Tautomers for Aurora Kinase A Selectivity” J. Comput. Aided Mol. Design 2015, 29, 89-100. (SCI: 4.179)(21/72, BIOPHYSICS) Times Cited: 36

2014

  1. Velu, A. B.; Chen, G. W.; Hsieh, P. T.; Horng, J. T.; Hsu, J. T.; Hsieh, H. P.; Chen, T. C.; Weng, K. F. Shih, S. R.* “BPR-3P0128 Inhibits RNA-dependent RNA Polymerase Elongation and VPg Uridylylation Activities of Enterovirus 71.” Antiviral Res. 2014, 112, 18-25. (SCI: 10.103)(6/37, VIROLOGY) Times Cited: 16
  2. Lee, C. C.; Shiao, H. Y.; Wang, W. C.; Hsieh, H. P.* “Small-molecule EGFR Tyrosine Kinase Inhibitors for the Treatment of Cancer” Opin. Investig. Drugs. 2014, 23, 1333-1348. (corresponding author) (SCI: 6.498)(41/279, PHARMACOLOGY & PHARMACY) Times Cited: 44
  3. Chen, Y. P.; Lin, H. J.; Chen, J. S.; Tsai, M. Y.; Hsieh, H. P.; Chang, J. Y.; Chen, N. F.; Chang, K. C.; Huang, W. T.; Su, W. C.; Yang, S. T.; Chang, W. C.; Hung, L. Y.*; Chen, T. Y.* “CDKN1A-mediated Responsiveness of MLL-AF4-positive Acute Lymphoblastic Leukemia to Aurora Kinase-A Inhibitors” J. Cancer 2014, 135, 751-762. (SCI: 7.316)(52/245, ONCOLOGY) Times Cited: 6
  4. Ke, Y. Y.; Coumar, M. S.; Shiao, H. Y.; Wang, W. C.; Chen, C. W.; Song, J. S.; Chen, C. H.; Lin, W. H.; Wu, S. H.; Hsu, J. T.; Chang, C. M.; Hsieh, H. P.* “Ligand Efficiency Based Approach for Efficient Virtual Screening of Compound Libraries” J. Med. Chem. 2014, 83, 226-235. (corresponding author) (SCI: 7.088)(5/63, CHEMISTRY, MEDICINAL) Times Cited: 11
  5. Wang, W.C.; Shiao, H. Y.; Lee, C. C.; Fung, K. S.; Hsieh, H. P.* “Anaplastic Lymphoma Kinase (ALK) Inhibitors: A Review of Design and Discovery” MedChemComm. 2014, 5, 1266–1279. (corresponding author) (SCI: 5.121)(18/63, CHEMISTRY, MEDICINAL) Times Cited: 20
  6. Chang Hsu, Y.; Ke, Y. Y.; Shiao, H. Y.*; Lee, C. C.; Lin, W. H.; Chen, C. H.; Yen, K. J.; Hsu, J. T.; Chang, C.; Hsieh, H. P.* “Facile Identification of Dual FLT3-Aurora A Inhibitors: A Computer-Guided Drug Design Approach” ChemMedChem, 2014, 5, 953-961. (Selected as the Front Cover) (corresponding author) (SCI: 3.540)(34/63, CHEMISTRY, MEDICINAL) Times Cited: 25

2013

  1. Hou, C.C.; Tsai, T. L.; Su, W. P.; Hsieh, H. P.; Yeh, C. S.; Shieh, D. B.; Su, W. C. “Pronounced Induction of Endoplasmic Reticulum Stress and Tumor Suppression by Surfactant-free Poly(lactic-co-glycolic acid) Nanoparticles via Modulation of the PI3K Signaling Pathway” J. Nanomedicine. 2013, 8, 2689–2707. (SCI: 6.4)(28/276, PHARMACOLOGY & PHARMACY) Times Cited: 10
  2. Shiao, H. Y.; Coumar, M. S.; Chang, C. W.; Ke, Y. Y.; Chi, Y. H.; Chu, C. Y.; Sun, H. Y.; Chen, C. H.; Lin, W. H.; Fung, K. S.; Kuo, P. C.; Huang, C. T.; Chang, K. Y.; Lu, C. T.; Hsu, J. T.; Chen, C. T.; Jiang, W. T.; Chao, Y. S.; Hsieh, H. P.* “Optimization of Ligand and Lipophilic Efficiency To Identify an in Vivo Active Furano-Pyrimidine Aurora Kinase Inhibitor” Med. Chem. 2013, 56, 5247–5260. (NSC-101-2113-M-400-002-MY4) (corresponding author) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 36
  3. Wang, X.; Wu, E.; Wu, J.; Wang, T. L.; Hsieh, H. P.; Liu, X.* “An Antimitotic and Antivascular Agent BPR0L075 Overcomes Multidrug Resistance and Induces Mitotic Catastrophe in Paclitaxel-Resistant Ovarian Cancer Cells” PLoS One. 2013, 8, e65686. (SCI: 3.24)(26/72, MULTIDISCIPLINARY SCIENCES) Times Cited: 21
  4. Wu, J. M.; Chen, C. T.; Coumar, M. S.; Lin, W. H.; Chen, Z. J.; Hsu, J. T.; Peng, Y. H.; Shiao, H. Y.; Lin, W. H.; Chu, C. Y.; Wu, J. S.; Lin, C. T.; Chen, C. P.; Hsueh, C. C.; Chang, K. Y.; Kao, L. P.; Huang, C. Y.; Chao, Y. S.; Wu, S. Y.*; Hsieh, H. P.*; Chi, Y. H.* “Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules” Natl. Acad. Sci. U. S. A. 2013, 110, E1779-1787. (NSC-101-2113-M-400-002-MY4) (corresponding author) (SCI: 11.205)(8/72, MULTIDISCIPLINARY SCIENCES) Times Cited: 34
  5. Peng, Y. H.; Shiao, H. Y.; Tu, C. H.; Liu, P. M.; Hsu, J. T.; Amancha, P. K.; Wu, J. S.; Coumar, M. S.; Chen, C. H.; Wang, S. Y.; Lin, W. H.; Sun, H. Y.; Chao, Y. S.; Lyu, P. C.; Hsieh, H. P.*; Wu, S. Y.* “Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors” Med. Chem. 2013, 56, 3889-3903. (NSC-101-2113-M-400-002-MY4) (corresponding author) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 76
  6. Shionome, Y.; Lin, W. H.; Shiao H. Y.; Hsieh H. P.; Hsu J. T.; Ouchi, T.* “A Novel Aurora-A Inhibitor, BPR1K0609S1, Sensitizes Colorectal Tumor Cells to 5-Fluorofracil (5-FU) treatment” J. Biol. Sci. 2013, 9, 403-411. (SCI: 6.582)(57/295, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 10
  7. Hsu, K. C.; Hung, H. C.; Horng, J. T.; Fang, M. Y.; Chang, C. Y.; Li, L. T.; Chen, Y. C.; Chou, D. L.; Chang, C. W.; Hsieh, H. P.; Yang, J. M.; Hsu, J. T.* “Parallel Screening of Wild-type and Drug-resistant Targets for Anti-resistance Neuraminidase Inhibitors” PLoS One. 2013, 8, e56704. (SCI: 3.24)(26/72, MULTIDISCIPLINARY SCIENCES) Times Cited: 9
  8. Ke, Y. Y.; Shiao, H. Y.; Hsu, Y. C.; Chu, C. Y.; Wang, W. C.; Lee, Y. C.; Lin, W. H.; Chen, C. H.; Hsu, J. T.; Chang, C. W.; Lin, C. W.; Yeh, T. K.; Chao, Y. S.; Coumar, M. S.*; Hsieh, H. P.* “3D-QSAR-Assisted Drug Design: Identification of a Potent Quinazoline-Based Aurora Kinase Inhibitor” ChemMedChem. 2013, 8, 136-148. (corresponding author) (SCI:3.466)(32/62, CHEMISTRY, MEDICINAL) Times Cited: 25
  9. Hsieh, H. P.; Chen, A. C.; Villarante, N. R.; Chuang, G. J.*; Liao, C. C.* “Substituent Effects on the Photorearrangements of Unsymmetrically Substituted Diazinobarrelenes” RSC Adv., 2013, 3, 1165-1178. (SCI: 3.361)(81/178, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 3

2012

  1. Shiao, H. Y.*; Kuo, C. C.; Horng, J. T.; Shih, S. R.; Chang, S. Y.; Liao, C. C.; Hsu, J. T.; Amancha, P. K.; Chao, Y. S.; Hsieh, H. P.* “An Efficient, Mild and Scalable Synthesis of Bioactive Compounds Containing the Angelicin Scaffold” Chin. Chem. Soc. 2012 59, 1548-1554. (Selected as the Front Cover) (NSC-98-2119-M-400-001-MY3) (corresponding author) (SCI:1.967)(119/178, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 5
  2. Yeh, J. Y.; Coumar, M. S.; Shiao, H. Y.; Lin, T. J.; Lee, Y. C.; Hung, H. C.; Ko, S.; Kuo, F. M.; Fang, M. Y.; Huang, Y. L.; Hsu, J. T.; Yeh, T. K.; Shih, S. R.; Chao, Y. S.; Horng, J. T.*; Hsieh, H. P.* “Anti-influenza Drug Discovery: Identification of an Orally Bioavailable Quinoline Derivative through Activity- and Property-Guided Lead Optimization” 2012, 9, 1546-1550. (corresponding author) (SCI:3.466) (32/62, CHEMISTRY, MEDICINAL) Times Cited: 5
  3. Liu, L.; Beck, H.; Wang, X.; Hsieh, H. P.; Mason, R. P.; Liu, X.* “Tubulin-Destabilizing Agent BPR0L075 Induces Vascular-Disruption in Human Breast Cancer Mammary Fat Pad Xenografts” PLoS One 2012, 7, e43314. (SCI: 3.24)(26/72, MULTIDISCIPLINARY SCIENCES) Times Cited: 23
  4. Hsu, J. T.; Yeh, J. Y.; Lin, T. J.; Li, M. L.; Wu, M. S.; Hsieh, C. F.; Chou, Y. C.; Tang, W. F.; Lau, K. S.; Hung, H. C.; Fang, M. Y.; Ko, S.; Hsieh, H. P.*; Horng, J. T.* “Identification of BPR3P0128 as an Inhibitor of Cap-Snatching Activities of Influenza Virus” Agents Chemother. 2012 56, 647-657. (corresponding author) (SCI: 5.191)(57/276, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY) Times Cited: 40
  5. Shiao, H. Y.*; Chiang, N. J.; Hsieh, H. P.* “Anaplastic Lymphoma Kinase (ALK) Inhibitors: New Cancer Breakthroughs for Lung Cancer ” Cancer Res. Pract. 2012, 27, 143-156. (corresponding author) (awardee invited article)
  6. Lin, W. H.; Song, J. S.; Lien, T. W.; Chang, C. Y.; Wu, S. H.; Huang, Y. W.; Chang, T. Y.; Fang, M. Y.; Yen, K. J.; Chen, C. H.; Chu, C. Y.; Hsieh, H. P.; Chen, Y. R.; Chao, Y. S.; Hsu, J. T.* “A High-throughput Cell-based Screening for L858R/T790M Mutant Epidermal Growth Factor Receptor Inhibitors ” Anticancer Res. 2012, 32, 147-151. (SCI: 2.48)(210/242, ONCOLOGY) Times Cited: 3

2011

  1. Lai, M. J.; Chang, J. Y.; Lee, H. Y.; Kuo, C. C.; Lin, M. H.; Hsieh, H. P.; Chang, C. Y.; Wu, J. S.; Wu, S. Y.; Shey, K. S.; Liou, J. P.* ” Synthesis and Biological Evaluation of 1-(4′-Indolyl and 6′-Quinolinyl)indoles as a New Class of Potent Anticancer Agents” Eur. J. Med. Chem. 2011, 46, 3623-3629. (SCI: 6.514)(4/62, CHEMISTRY, MEDICINAL) Times Cited: 30
  2. Cheung, C. H.; Lin, W. H.; Hsu, J. T.; Hour, T. C.; Yeh, T. K.; Ko, S.; Lien, T. W.; Coumar, M. S.; Liu, J. F.; Lai, W. Y.; Shiao, H. Y.; Lee, T. R.; Hsieh, H. P.*; Chang, J. Y.* “BPR1K653, a Novel Aurora Kinase Inhibitor, Exhibits Potent Anti-Proliferative Activity in MDR1 (P-gp170)-Mediated Multidrug-Resistant Cancer Cells” PLoS One 2011, 6, e23485. (corresponding author) (SCI: 3.24)(26/72, MULTIDISCIPLINARY SCIENCES) Times Cited: 17
  3. Lin, P. H.; Ke, Y. Y.; Su, C. T.; Shiao, H. Y.; Hsieh, H. P.; Zhao, Y. K.; Lee, C. N.; Kao, C. L.; Chao, Y. S.; Chang, S. Y.* “Inhibition of HIV-1 Tat-mediated Transcription by a Coumarin Derivative BPRHIV001 through Akt Pathway” J. Virol. 2011, 85, 9114-9126. (NSC97-2321-B-400-002) (SCI: 5.103)(9/37, VIROLOGY) Times Cited: 21
  4. Cheung, C. H.; Coumar, M. S.; Chang, J. Y. *; Hsieh, H. P.* “Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10)” Expert Opin. Ther. Pat. 2011, 21, 857-884. (NSC-98-2119M-400-001-MY3) (corresponding author) (SCI: 6.681)(4/62, CHEMISTRY, MEDICINAL) Times Cited: 36
  5. Tung, Y. S.; Coumar, M. S.; Wu, Y. S.; Shiao, H. Y.; Chang, J. Y.; Liou, J. P.; Shukla, P.; Chang, C. W.; Chang, C. Y.; Kuo, C. C.; Yeh, T. K.; Lin, C. Y.; Wu, J. S.; Wu, S. Y.; Liao, C. C.; Hsieh, H. P.* “Scaffold-Hopping Strategy: Synthesis and Biological Evaluation of 5,6-Fused Bicyclic Heteroaromatics To Identify Orally Bioavailable Anticancer Agents” J. Med. Chem. 2011, 54, 3076-3080. (NSC-98-2119M-400-001-MY3) (corresponding author) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 83
  6. Chuang, H. Y.; Chang, J. Y.; Lai, M. J.; Kuo, C. C.; Lee, H. Y.; Hsieh, H. P.; Chen, Y. J.; Chen, L. T.; Pan, W. Y.; Liou, J. P.* “2-Amino-3,4,5-Trimethoxybenzophenones as Potent Tubulin Polymerization Inhibitors” ChemMedChem. 2011, 6, 450-456. (SCI: 3.466)(32/62, CHEMISTRY, MEDICINAL) Times Cited: 12

2010

  1. Wu, C. H.; Coumar, M. S.; Chu, C. Y.; Lin, W. H.; Chen, Y. R.; Chen, C. T.; Shiao, H. Y.; Rafi, S.; Wang, S. Y.; Hsu, H.; Chen, C. H.; Chang, C. Y.; Chang, T. Y.; Lien, T. Z.; Fang, M. Y.; Yeh, K. C.; Chen, C. P.; Yeh, T. K.; Hsieh, S. H.; Hsu, J. T.; Liao, C. C.; Chao, Y. S.; Hsieh, H. P.* “Design and Synthesis of Tetrahydropyridothieno[2,3-d]pyrimidine Scaffold based Epiderml Growth Factor Receptor (EGFR) Kinase Inhibitors: The Role of Side Chain Chirality and Michael Acceptor Group for Maximal Potency” J. Med. Chem. 2010, 53, 7316–7326. (NSC-98-2119M-400-001-MY3) (corresponding author) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 101
  2. Peng, Y. H.; Coumar, M. S.; Leou, J. S.; Wu, J. S.; Shiao, H. Y.; Lin, C. H.; Lin, W. H.; Lien, T. W.; Chen, X.; Hsu, J. T.; Chao, Y. S.; Huang, C. F.; Lyu, P. C; Hsieh, H. P.*; Wu, S. Y.* “Structural Basis for the Improved Potency of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists” ChemMedChem. 2010, 5, 1707-1716. (corresponding author) (SCI: 3.466)(32/62, CHEMISTRY, MEDICINAL) Times Cited: 7
  3. Cheung, C. H.; Wu, S. Y.; Lee, T. R.; Chang, C. Y.; Wu, J. S.; Hsieh, H. P.; Chang, J. Y.* “Cancer Cells Acquire Mitotic Drug Resistance Properties through Beta I-tubulin Mutations and Alterations in the Expression of Beta-tubulin Isotypes” PLoS One 2010, 5, e12564. (SCI: 3.24)(26/72, MULTIDISCIPLINARY SCIENCES) Times Cited: 38
  4. Coumar, M. S.; Chu, C. Y.; Lin, C. W.; Shiao, H. Y.; Ho, Y. L.; Reddy, R.; Lin, W. H.; Chen, C. H.; Peng, Y. H.; Leou, J. S.; Lien, T. W.; Huang, C. T.; Fang, M. Y.; Wu, S. H.; Wu, J. S.; Chittimalla, S. K.; Song, J. S.; Hsu, J. T.; Wu, S. Y.; Liao, C. C.; Chao, Y. S.; Hsieh, H. P.* “Fast-forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor Lead Identification”, J. Med. Chem. 2010, 53, 4980-4988. (NSC-98-2119M-400-001-MY3) (corresponding author) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 61
  5. Chen C. P.; Hu, C. B.; Yeh, K. C.; Song, J. S.; Yeh, T. K.; Tung, F. F.; Hwang, L. L.; Tseng, H. Y.; Huang, Y. C.; Shy, H. S.; Hsieh, S. H.; Shen, C. C.; Wang, H. S.; Hsieh, H. P.; Liou, J. P.; Chao, Y. S.; Chen, C. T.* “Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075”, Anticancer Res. 2010, 30, 2813-2822. (SCI: 2.48) (210/242, ONCOLOGY) Times Cited: 12
  6. Chen, J. C.; Uang, B. J.; Lyu, P. C.; Chang, J. Y.; Liu, K. J.; Kuo, C. C.; Hsieh, H. P.; Wang, H. C.; Cheng, C. S.; Chang, Y. H.; Chang, M. D.*; Chang, W. S.*; Lin, C. C.* “Design and Synthesis of alpha-Ketoamides as Cathepsin S Inhibitors with Potential Applications against Tumor Invasion and Angiogenesis”, J. Med. Chem. 2010, 53, 4545-4549. (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 47
  7. Nien, C.Y.; Chen, Y. C.; Kuo, C. C.; Hsieh, H. P.; Chang, C. Y.; Wu, J. S.; Wu, S. Y.; Liou, J. P.*; Chang, J. Y.* “5-Amino-2-Aroylquinolines as Highly Potent Tubulin Polymerization Inhibitors”, J Med Chem. 2010, 53, 2309-2313. (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 73
  8. Yeh, J. Y.; Coumar, M. S.; Horng, J. T.; Shiao, H. Y.; Kuo, F. M.; Lee, H. L.; Chen, I. C.; Chang, C. W.; Tang, W. F.; Tseng, S. N.; Chen, C. J.; Shih, S. R.; Hsu, J. T.; Liao, C. C.; Chao, Y. S.; Hsieh, H. P.* “Anti-Influenza Drug Discovery: Structure-Activity Relationship and Mechanistic Insight into Novel Angelicin Derivatives”, J Med Chem. 2010, 53, 1519-1533. (corresponding author) (NSC–95-2745-B-400-002, NSC-97-2321-B-182-003, NSC-98-2323-B-400-003) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 127
  9. Shih, S. R.; Chu, T. Y.; Reddy, G. R.; Tseng, S. N.; Chen, H. L.; Tang, W. F.; Wu, M. H.; Yeh, J. Y.; Chao, Y. S.; Hsu, J. T.; Hsieh, H. P.*; Horng, J. T.* “Pyrazole Compound BPR1P0034 with Potent and Selective Anti-Influenza Virus Activity”, J. Biomed. Sci. 2010, 17, 13-23. (corresponding author) (NSC97-2321-B-400-002) (SCI: 8.41)(15/140, MEDICINE, RESEARCH & EXPERIMENTAL) Times Cited: 82
  10. Coumar, M. S.; Tsai, M. T.; Chu, C. Y.; Uang, B. J.; Lin, W. H.; Chang, C. Y.; Chang, T. Y.; Leou, J. S.; Teng, C. H.; Wu, J. S.; Fang, M. Y.; Chen, C. H.; Hsu, J. T.; Wu, S. Y.; Chao, Y. S.; Hsieh, H. P.* “Identification, SAR Studies, and X-ray Co-crystallographic Analysis of a Novel Furanopyrimidine Aurora Kinase A Inhibitor”, ChemMedChem. 2010, 5, 255-267. (corresponding author) (NSC-98-2119M-400-001-MY3) (SCI: 3.466)(32/62, CHEMISTRY, MEDICINAL) Times Cited: 24
  11. Lin, I. H.; Hsu, C. C.; Wang, S. H.; Hsieh, H. P.*; Sun, Y. C.* “Comparative Molecular Field Analysis of Anti-tubulin Agents with Indole Ring Biding” J. Theor. Comput. Chem. 2010, 9, 279–291. (corresponding author) (SCI: 0.939)(153/178, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 1
  12. Shih, S. R.*; Horng, J. T.; Poon, L. L.; Chen, T. C.; Yeh, J. Y.; Hsieh, H. P.; Tseng, S. N.; Chiang, C.; Li, W. L.; Chao, Y. S.; Hsu, J. T. “BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses”, J. Antimicrob. Chemother. 2010, 65, 63-71. (NSC-97-2321-B-182-003) (SCI: 5.79)(43/276, PHARMACOLOGY & PHARMACY) Times Cited: 20

2009

  1. Wu, Y. S.; Coumar, M. S.; Chang, J. Y.; Sun, H. Y.; Kuo, F. M.; Kuo, C. C.; Chen, Y. J.; Chang, C. Y.; Hsiao, C. L.; Liou, J. P.; Chen, C. P.; Yao, H. T.; Chiang, Y. K.; Tan, U. K.; Chen, C. T.; Chu, C. Y.; Wu, S. Y.; Yeh, T. K.; Lin, C. Y.; Hsieh, H. P.* “Synthesis and Evaluation of 3-Aroylindoles as Anticancer Agents: Metabolite Approach”, J. Med. Chem. 2009, 52, 4941-4945. (corresponding author) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 80
  2. Chiang, Y. K.; Kuo, C. C.; Wu, Y. S.; Chen, C. T.; Coumar, M. S.; Wu, J. S.; Hsieh, H. P.; Chang, C. Y.; Jseng, H. Y.; Wu, M. H.; Leou, J. S.; Song, J. S.; Chang, J. Y.; Lyu, P. C.; Chao, Y. S.; Wu, S. Y.* “Generation of Ligand-Based Pharmacophore Model and Virtual Screening for Identification of Novel Tubulin Inhibitors with Potent Anticancer Activity”, J. Med. Chem. 2009, 52, 4221-4233. (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 49
  3. Cheung, C. H.; Chen, H. H.; Kuo, C. C.; Chang, C. Y.; Coumar, M. S.; Hsieh, H. P.; Chang, J. Y.* “Survivin Counteracts the Therapeutic Effect of Microtubule De-stabilizers by Stabilizing Tubulin Polymers”, Mol. Cancer 2009, 8:43-58. (SCI: 27.401)(10/242, ONCOLOGY) Times Cited: 59
  4. Cheung, C. H.; Coumar, M. S.; Hsieh, H. P.*; Chang, J. Y.* “Aurora Kinase Inhibitors in Preclinical and Clinical Testing”, Expert Opin. Investig. Drugs 2009, 18, 379-398. (corresponding author) (SCI: 6.206)(30/276, PHARMACOLOGY & PHARMACY) Times Cited: 84
  5. Lin, C. H.; Peng, Y. H.; Coumar, M. S.; Chittimalla, S. K.; Liao, C. C.; Lyn, P. C.; Huang, C. C.; Lien, T. W.; Lin, W. H.; Hsu, J. T.; Cheng, J. H.; Chen, X.; Wu, J. S.; Chao, Y. S.; Lee, H. J.; Juo, C. G.; Wu, S. Y.*; Hsieh, H. P.* “Design and Structural Analysis of Novel Pharmacophores for Potent and Selective Peroxisome Proliferator-activated Receptor Gamma Agonists”, J. Med. Chem. 2009, 52, 2618-2622. (corresponding author) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 18
  6. Lai, M.J.; Kuo, C. C.; Yeh, T. K.; Hsieh, H. P.; Chen, L. T.; Pan, W. Y.; Hsu, K. Y.; Chang, J. Y.; Liou, J. P.* “Synthesis and Structure-activity Relationships of 1-Benzyl-4,5,6- trimethoxyindoles as A Novel Class of Potent Antimitotic Agents.”, ChemMedChem. 2009, 4, 588-593. (SCI: 3.466) (32/62, CHEMISTRY, MEDICINAL) Times Cited: 12
  7. Chen, K. F.; Yeh, P. Y.; Hsu, C.; Hsu, C. H.; Lu, Y. S.; Hsieh, H. P.; Chen, P. J.; Cheng, A. L.* “Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway”, J. Biol. Chem. 2009, 284, 11121-11133. (SCI: 5.157)(86/295, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 83
  8. Coumar, M. S.; Cheung, A. C. H.; Chang, J. Y.; Hsieh, H. P.* “Advances in Aurora Kinase Inhibitor Patents”, Expert Opin. Ther. Pat. 2009, 19, 321-356. (corresponding author) (SCI: 6.681)(4/62, CHEMISTRY, MEDICINAL) Times Cited: 25
  9. Coumar, M. S.; Leou, J. S.; Shukla, P.; Wu, J. S.; Dixit, A. K.; Lin, W. H.; Chang, C. Y.; Lien, T. W.; Tan, U. K.; Chen, C. W.; Hsu, J. T.; Chao, Y. S. Wu, S. Y.*; Hsieh, H. P.* “Structure-based Drug Design of Novel Aurora Kinase A Inhibitors: Structural Basis for Potency and Specificity”, J. Med. Chem. 2009, 52, 1050–1062. (corresponding author) (NSC95-2113-B-400 -001-MY3 and NSC-95-2752-B-007-002-PAE) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 59
  10. Hung, H. C.; Tseng, C. P.; Yang, J. M.; Ju, Y. W.; Tseng, S. N.; Chen, Y. F.; Chao, Y. S.; Hsieh, H. P.; Shih, S. R.; Hsu, J. T.* “Aurintricarboxylic Acid Inhibits Influenza Virus Neuraminidase”, Antiviral Res. 2009, 81, 123-131. (SCI: 5.97)(8/37, VIROLOGY)Times Cited: 87

2008

  1. Reddy, G. R.; Kuo, C. C.; Tan, U. K.; Coumar, M. S.; Chang, C. Y.; Chiang, Y. K.; Lai, M. J.; Yeh, J. Y.; Wu, S. Y.; Chang, J. Y.; Liou, J. P.*; Hsieh, H. P.* “Synthesis and Structure-Activity Relationships of 2-Amino-1-aroylnaphthalene and 2-Hydroxy-1-aroyl naphthalenes as Potent Antitubulin Agents”, J. Med. Chem. 2008, 51, 8163-8167. (corresponding author) (NSC95-2113-B-400-001-MY3) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 26
  2. Liou, J. P.; Wu, Z. Y.; Kuo, C. C.; Chang, C. Y.; Lu, P. Y.; Chen, C. M.; Hsieh, H. P.*; Chang, J. Y.* “Discovery of 4-Amino and 4-Hydroxy-1-Aroylindoles as Potent Tubulin Polymerization Inhibitors”, J. Med. Chem. 2008, 51, 4351-4355. (corresponding author) (NSC95-2113-B-400-001- MY3) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 69
  3. Su, C. T.; Hsu, J. T; Hsieh, H. P.; Lin, P. H.; Chen, T. C.; Kao, C. L.; Lee, C. N.; Chang, S. Y.* “Anti-HSV Activity of Digitoxin and its Possible Mechanisms”, Antiviral Res. 2008, 79, 62-70. (SCI: 5.97)(8/37, VIROLOGY) Times Cited: 61
  4. Lin, W. H.; Song, J. S.; Chang, T. Y.; Chang, C. Y.; Fu, Y. N.; Yeh, C. L.; Wu, S. H.; Huang Y. W.; Fang, M. Y.; Lien, T. W.; Hsieh, H. P.; Chao, Y. S.; Huang, S. F.; Tsai, S. F.; Wang, L. M.; Hsu, J. T. *; Chen, Y. R.* “A Cell-based High-throughput Screen for Epidermal Growth Factor Receptor Pathway Inhibitors”, Anal. Biochem. 2008, 377, 89-94. (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 10
  5. Chou, Y. C.; Prakash, E.; Huang, C. F.; Lien, T. W.; Chen, X.; Su, I. J.; Chao, Y. S.; Hsieh, H. P.*; Hsu, J. T.* “Bioassay-Guided Purification and identification of PPAR Agonists from Chlorella Sorokiniana“, Phytother. Res. 2008, 22, 605-613. (corresponding author) (SCI: 5.882)(8/62, CHEMISTRY, MEDICINAL) Times Cited: 27
  6. Chou, C. Y.; Chien, C. H.; Han, Y. S.; Prebanda, M. T.; Hsieh, H. P.; Turk, B.; Chang, G. G.; Chen, X.* “Thiopurine Analogues Inhibit Papain-like Protease of Severe Acute Respiratory Syndrome Coronavirus”, Biochem. Pharmacol. 2008, 75, 1601-1609. (SCI: 5.858) PHARMACOLOGY & PHARMACY (39/276)(39/276, PHARMACOLOGY & PHARMACY) Times Cited: 69
  7. Romagnoli, R.; Baraldi, P. G.; Sarkar, T.; Carrion, M. D.; Cara, C. L.; Cruz-Lopez, O.; Preti, D.; Tabrizi, M. A.; Tolomeo, M.; Grimaudo, S.; Di Cristina, A.; Zonta, N.; Balzarini, J.; Brancale, A.; Hsieh, H. P.; Hamel, E.* “Synthesis and Biological Evaluation of 1-Methyl- 2-(3′,4′,5′-trimethoxybenzoyl)-3-aminoindoles as a New Class of Antimitotic Agents and Tubulin Inhibitors”, J. Med. Chem. 2008, 51, 1464-1468. (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 90
  8. Chittimalla, S. K.; Chang, T. C.; Liu, T. C.; Hsieh, H. P.*; Liao, C. C.* “Reactions of 2-Hydroxybenzophenones with Corey-Chaykovsky Reagent”, Tetrahedron 2008, 64, 2586-2595. (corresponding author) (NSC95-2113-B-400-001-MY3) (SCI: 2.457)(27/57, CHEMISTRY, ORGANIC) Times Cited: 30
  9. Coumar, M. S.; Wu, J. S.; Leou, J. S.; Tan, U. K.; Chang, C. Y.; Chang, T. Y.; Lin, W. H.; Hsu, J. T.; Chao, Y. S.; Wu, S. Y.*; Hsieh, H. P.* “Aurora Kinase A Inhibitors: Identification, SAR Exploration and Molecular Modeling of 6,7-Dihydro-4H-pyrazolo[1,5-a]pyrrolo[3,4-d] pyrimidine-5,8-dione Scaffold”, Bioorg. Med. Chem. Lett. 2008, 18, 1623-1627. (corresponding author) (NSC95-2113-B-400-001-MY3) (SCI: 2.823)(41/62, CHEMISTRY, MEDICINAL) Times Cited: 29
  10. Shiao, H. Y., Hsieh, H. P.*; Liao, C. C.* “First Total Syntheses of (+/-)-Annuionone B and (+/-)-Tanarifuranonol”, Org. Lett. 2008, 10, 449-452. (corresponding author) (NSC95-2113-B-400-001-MY3) (SCI: 6.005)(6/57, CHEMISTRY, ORGANIC) Times Cited: 31
  11. Kao, Y. H.; Hsieh, H. P.; Chitlimalla, S. K.; Pan, W. Y.; Kuo, C. C.; Tsai, Y. C.; Lin, W. H.; Chuang, S. E.; Chang, J. Y.* “A Novel Peroxisome Proliferator-activated Receptor Alpha/Gamma Agonist, BPR1H0101, Inhibits Topoisomerase II Catalytic Activity in Human Cancer Cells”, Anti-cancer Drugs, 2008, 19, 151-158. (SCI: 2.248)(218/242, ONCOLOGY) Times Cited: 6

2007

  1. Liou, J. P.; Wu, C. Y.; Hsieh, H. P.; Chang, C. Y.; Chen, C. M.; Kuo, C. C.; Chang, J. Y.* “4- and 5-Aroylindoles as Novel Classes of Potent Antitubulin Agents”, J. Med. Chem. 2007, 50, 4548-4552. (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 61
  2. Chen, C. C.; Chen, L. T.; Tsou, T. C.; Pan, W. Y.; Kuo, C. C.; Liu, J. F.; Yeh, S. C.; Tasi, F. Y.; Hsieh, H. P.; Chang, J. Y.* “Combined Modalities of Resistance in an Oxaliplatin-Resistant Human Gastric Cancer Cell Line with Enhanced Sensitivity to 5-Fluorouracil”, Br. J. Cancer 2007, 97, 334-344. (SCI: 7.64)(39/242, ONCOLOGY) Times Cited: 34
  3. Yao, H. T.; Wu, Y. S.; Chang, Y. W.; Hsieh, H. P.; Chen, W. C.; Lan, S. J.; Chen, C. T.; Chao, Y. S.; Chang, L.; Sun, H. Y.; Yeh, T. K.* “Biotransformation of BPR0L075, A Novel Antimicrotubule Agent, By Mouse, Rat, Dog and Human Liver Microsomes”, Drug Metab. Dispos. 2007, 35, 1042-1049. (SCI: 3.922)(115/276, PHARMACOLOGY & PHARMACY) Times Cited: 9
  4. Coumar, M. S.; Chang, C. N.; Chen, C. T.; Chen, X.; Chien, C. H.; Tsai, T. Y.; Cheng, J. H.; Wu, H. Y.; Han, C. H.; Wu, S. H.; Huang, Y. W.; Hsu, T.; Hsu, L. J.; Chao, Y. S.; Hsieh, H. P.*; Jiaang, W. T.* “3-[2-((2S)-2-Cyano-pyrrolidin-1-yl)- 2-oxo-ethylamino]-3-methyl-butyramide Analogues as Selective DPP-IV Inhibitors for the Treatment of Type-II Diabetes”, Bioorg. Med. Chem. Lett. 2007, 17, 1274-1279. (corresponding author) (SCI: 2.823, CHEMISTRY, MEDICINAL)(41/62) Times Cited: 11
  5. Chen, C. N.; Huang, H. H.; Wu, C. L.; Lin, C. P. C.; Hsu, J. T. A.; Hsieh, H. P.; Chuang, S. E.; Lai, G. M.* “Isocostunolide, a Sesquiterpene Lactone, Induces Mitochondrial Membrane Depolarization and Caspase-dependent Apoptosis in Human Melanoma Cells”, Cancer Lett. 2007,246, 237-252. (SCI: 8.679)(34/242, ONCOLOGY) Times Cited: 54
  6. Chang Y. W.; Chen, W. C.; Lin, K. T.; Chang, L., Yao, H. T.; Hsieh, H. P.; Lan, S. J.; Chen, C. T.; Chao, Y. S.; Yeh, T. K.* “Development and Validation of a Liquid Chromatography-tandem mass Spectrometry for the Determination of BPR0L075, a Novel Antimicrotuble Agent, in Rat Plasma: Application to a Pharmacokinetic Study”, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 846, 162-168. (SCI: 3.205)(36/87, CHEMISTRY, ANALYTICAL) Times Cited: 9
  7. Hsieh, H. P.; Hsu, J. T.* “Strategies of Development of Antiviral Agents Directed against Influenza Virus Replication”, Curr. Pharm. Design 2007, 13, 3531-3542. (SCI: 3.116)(159/276, PHARMACOLOGY & PHARMACY) Times Cited: 92

2006

  1. Chang, Y. W.; Yeh, T. K.; Lin, K. T.; Chen, W. C.; Yao, H. T.; Lan, S.. J.; Wu, Y. S.; Hsieh, H. P.; Chen, C. M.; Chen, C. T.* “Pharmacokinetics of Anti-SARS-CoV Agent Niclosamide and Its Analogs in Rats”, J. Food Drug Analysis, 2006, 14, 329-333. (SCI: 6.079)(34/276, PHARMACOLOGY & PHARMACY) Times Cited: 46
  2. Chang, J. Y.; Hsieh, H. P.; Chang, C. Y.; Hsu, K. S.; Chiang, Y. F.; Chen, C. M.; Kuo, C. C.; Liou, J. P. * “7-Aroyl-aminoindoline-1-sulfonamides as a Novel Class of Potent Antitubulin Agents”, J. Med. Chem. 2006, 49, 6656-6659. (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 78
  3. Mahindroo, N.; Peng, Y. H.; Lin, C. H.; Tan, U. K.; Prakash, E.; Lien, T. W.; Lu, I. L.; Lee, H. J.; Hsu, J. T. A.; Chen, X.; Liao, C. C.; Lyu, P. C.; Chao, Y. S.; Wu, S. Y.*; Hsieh, H. P.* “Structural Basis for the Structure-Activity Relationships of Peroxisome Proliferator-Activated Receptor Agonists”, J. Med. Chem. 2006, 49, 6421-6424. (corresponding author) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 29
  4. Liou, J. P.; Mahindroo, N.; Chang, C. W.; Guo, F. M.; Lee, S. W. H.; Tan, U. K.; Yeh, T. K.; Kuo, C. C. ; Chang, Y. W.; Lu, P. H.; Tung, Y. S.; Lin, K. T.; Chang, J. Y.*; Hsieh, H. P.* “Structure-Activity Relationship Studies of 3-Aroylindoles as Potent Antimitotic Agents”, ChemMedChem, 2006, 1, 1106-1118. (corresponding author) (SCI: 3.466)(32/62, CHEMISTRY, MEDICINAL)Times Cited: 43
  5. Lu, I. L.; Mahindroo, N.; Liang, P. H.; Peng, Y. H.; Kuo, C. J.; Tsai, K. C.; Hsieh, H. P.*; Chao, Y. S.; Wu, S. Y.* “Structure-based Drug Design and Structural Biology Study of Novel Nonpeptide Inhibitors of Severe Acute Respiratory Syndrome Coronavirus Main Protease”, J. Med. Chem. 2006, 49, 5154-5161. (corresponding author) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL)  Times Cited: 92
  6. Wu, Y. S.; Lin, W. S.; Hsu, J. T. A.*; Hsieh, H. P.* “Antiviral Drug Discovery against SARS-CoV”, Curr. Med. Chem. 2006, 13, 2003-2020. (corresponding author) (SCI: 4.53)(17/62, CHEMISTRY, MEDICINAL) Times Cited: 36
  7. Tsai, T. Y.; Coumar, M. S.; Hsu, T.; Hsieh, H. P.; Chien, C. H.; Chen, C. T.; Chang, C. N.; Lo, Y. K.; Wu, S. H.; Huang, C. Y.; Huang, Y. W.; Wang, M. H.;, Wu, H. Y.;, Lee, H. J.; Chen, X.; Chao, Y. S.; Jiaang, W. T.* “Substituted pyrrolidine-2,4-dicarboxylic Acid Amides as Potent Dipeptidyl Peptidase IV Inhibitors”, Bioorg. Med. Chem. Lett. 2006, 16, 3268-3272. (SCI: 2.823)(41/62, CHEMISTRY, MEDICINAL) Times Cited: 17
  8. Tsai, K. C.; Chen, S. Y.; Liang, P. H.; Lu, I. L.; Mahindroo, N.; Hsieh, H. P.; Chao, Y. S.; Liu, L.; Liu, D.; Lien, W.; Lin, T. H.*; Wu, S. Y.* “Discovery of a Novel Family of SARS-CoV Protease Inhibitors by Virtual Screening and 3D-QSAR Studies”, J. Med. Chem. 2006, 49, 3485-3495. (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 54
  9. Lu, I. L.; Huang, C. F.; Peng, Y. H.; Lin, Y. T.; Hsieh, H. P.; Chen, C. T.; Lien, T. W.; Lee, H. J.; Mahindroo, N.; Prakash, E.; Yueh, A.; Chen, H. Y.; Goparaju, C. M.; Chen, X.; Liao, C. C.; Chao, Y. S.; Hsu, J. T.*; Wu, S. Y.* “Structure-Based Drug Design of a Novel Family of PPARgamma Partial Agonists: Virtual Screening, X-ray Crystallography, and in Vitro/in Vivo Biological Activities”, J. Med. Chem. 2006, 49, 2703-2712. (NSC 92-2323-B-007-001 and NSC 93-2323-B-007-001) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 92
  10. Mahindroo, N.; Liou, J. P.; Chang, J. Y. *; Hsieh, H. P. * “Antitubulin Agents for Treatment of Cancer- A Medicinal Chemistry Update”, Expert Opin. Ther. Pat. 2006, 16, 647-691. (corresponding author) (SCI: 6.681)(4/62, CHEMISTRY, MEDICINAL) Times Cited: 73
  11. Mahindroo, N.; Wang, C. C.; Liao, C. C.; Huang, C. F.; Lu, I. L; Lien, T. W.; Peng, Y. H.; Huang, W. J.; Lin, Y. T.; Hsu, M. C.; Lin, C. H.; Tsai, C. H.; Hsu, J. T. A.; Chen, X.; Lyu, P. C.; Chao, Y. S.; Wu, S. Y.*; Hsieh, H. P.* “Indol-1-yl Acetic Acids as Peroxisome Proliferator-Activated Receptor Agonists – Design, Synthesis, Structural Biology, and Molecular Docking Studies”, J. Med. Chem. 2006, 49, 1212-1216. (corresponding author) (NSC 92-2323-B-007-001 and NSC 93-2323-B-007-001) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 69
  12. Tsu, H.; Chen, X.; Chen, C. T.; Lee, S. J.; Chang, C. N.; Kao, K. H.; Coumar, M. S.; Yeh, Y. T.; Chien, C. H.; Wang, H. S.; Lin, K. T.; Chang, Y. Y.; Wu, S. H.; Chen, Y. S.; Lu, I. L.; Wu, S. Y.; Tsai, T. Y.; Chen, W. C.; Hsieh, H. P.; Chao, Y. S.; Jiaang, W. T.* “2-[3-[2-[(2S)-2- Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]-1,2,3,4-tetrahydroisoquinoline: A Potent, Selective, and Orally Bioavailable Dipeptide-Derived Inhibitor of Dipeptidyl Peptidase IV”, J. Med. Chem. 2006, 49, 373-380. (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 25
  13. Hwang, D. R.; Wu, Y. S.; Chang, C. W.; Lien, T. W.; Chen, W. C. Tan, U. K.; Hsu, J. T.*; Hsieh, H. P.* “Anti-Hepatitis C Virus Agents: Synthesis and Structure-Activity Relationships Studies of Sesquiterpene Lactones Screened by Hepatitis C Virus Replicon System”, Bioorg. Med. Chem. 2006, 14, 83-91. (corresponding author) (SCI: 3.641)(29/62, CHEMISTRY, MEDICINAL) Times Cited: 103

2005

  1. Mahindroo, N.; Huang, C. F.; Peng, Y. H.; Wang, C. C.; Lien, T. W.; Liao, C. C.; Kumar, S.; Huang, W. J.; Chen, C. P.; Hsu, T. A.; Prakash, E.; Peng, C. H.; Lu, I. L; Chang, Y. W.; Chen, W. C.; Chen, C. T.; Goparaju, C. M. V.; Chen, Y. S.; Chen, Y. S.; Lan, S. J.; Yu, M. C.; Chen, X.; Chao, Y. S.; Wu, S. Y.*; Hsieh, H. P.* “Novel Indole–based Peroxisome Proliferator-Activated Receptors Agonists: Design, SAR, Structural Biology and Biological Activities”, J. Med. Chem. 2005, 48, 8194-8208. (corresponding author) (NSC 92-2323-B-007-001 and NSC 93-2323-B-007-001) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 84
  2. Chiu, J. J.*; Chen, L. J.; Chang, S. F.; Lee, P. L.; Lee, C.I.; Tsai, M. C.; Lee, D. Y.; Hsieh, H. P.; Usami, S.; Chien, S. “Shear Stress Inhibits Smooth Muscle Cell-Induced Inflammatory Gene Expression in Endothelial Cells. Role of NF-{kappa}B”, Arterioscler. Thromb. Vasc. Biol. 2005, 25, 963-969. (SCI: 8.313)(5/65, PERIPHERAL VASCULAR DISEASE)Times Cited: 46
  3. Hsieh, H. P.*; Liou, J. P.; Mahindroo, N. “Pharmaceutical Design of Antimitotic Agents Based on Combretastatins”, Curr. Pharm. Design, 2005, 11, 1655-1677. (corresponding author) (SCI: 3.116)(159/276, PHARMACOLOGY & PHARMACY) Times Cited: 160
  4. Chen, C. N.; Lin, C. P. C.; Huang, K. K.; Chen, H. W.; Hsieh, H. P.; Liang, P. H.; Hsu, J. T. A.* “Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3’-digallate (TF3)”, Evid. Based Complement Alternat. Med. 2005, 2, 209-215. (NSC93-2751- B-400-005-Y) (SCI: 2.63) (12/28, INTEGRATIVE & COMPLEMENTARY MEDICINE) Times Cited: 167

2004

  1. Hsu, J. T. A.; Kuo, C. J.; Hsieh, H. P.; Wang, Y. C.; Huang, K. K.; Lin, C. P. C.; Huang, P. F.; Chen, X.; Liang, P. H.* “Evaluation of Metal-Conjugated Compounds as Inhibitors of 3CL Protease of SARS-CoV”, FEBS Lett. 2004, 574, 116-120. (NSC93-2751-B-400- 005-Y) (SCI: 4.124)(131/295, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 84
  2. Liou, J. P.; Chang, Y. L.; Kuo, F. M.; Chang, C. W.; Tseng, H. Y., Wang, C. C.; Yang, Y. N.; Lee, S. J.*; Hsieh, H. P.* “Concise Synthesis and Structure-Activity Relationships of Combretastatin A-4 Analogues, 1-Aroylindoles and 3-Aroylindoles, as Novel Classes of Potent Antitubulin Agents”, J. Med. Chem. 2004, 47, 4247-4257. (corresponding author) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 175
  3. Juang, S. H.; Pan, W. Y.; Kuo, C. C.; Liou, J. P.; Chen, L. T.; Hsieh, H. P.; Chang, J. Y.* “A Novel Bis-benzylidenecyclopentanone Derivative, BPR0Y007, Inducing a Rapid Caspase Activation Involving Upregulation of Fas (CD95/APO-1) and Wild-type p53 in Human Oral Epidermoid Carcinoma Cells”, Biochem. Pharmacol. 2004, 68, 293-303. (SCI: 5.858)(39/276, PHARMACOLOGY & PHARMACY) Times Cited: 15
  4. Wu, C. J.; Jan, J. T.; Chen, C. M.; Hsieh, H. P.; Chao, Y. S.; Liu, H. W.; Liu, C. Y.; Huang, H. W.; Chen, S. C.; Hong, C. F.; Lin, R. K.; Huang, D. R.; Hsu, T. A.* “Inhibition of SARS-CoV Replication by Niclosamide”, Antimicrob. Agents Chemother. 2004, 48, 2693-2696. (SCI: 5.191)(57/276, PHARMACOLOGY & PHARMACY) Times Cited: 162
  5. Kuo, C. C.; Hsieh H. P.; Pan, W. Y.; Chen, C. P.; Liou, J. P.; Lee, S. J.; Chang, Y. L.; Chen, L. T.; Chen, C. T.*; Chang, J. Y.* “BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activity in Vivo“, Cancer Res. 2004, 64, 4621-4628. (SCI: 12.701)(17/242, ONCOLOGY) Times Cited: 187
  6. Liou, J. P.; Chang, J. Y.; Chang, C. W.; Chang, C. Y.; Mahindroo, N; Kuo, F. M.; Hsieh, H. P.* “Synthesis and Structure-Activity Relationship of 3-Amino benzophenones as Antimitotic Agents”, J. Med. Chem. 2004, 47, 2897-2905. (corresponding author) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 99

2003

  1. Lin, S. Y; Hsieh, H. P.; Peddinti, R. K.; Liao, C. C.* “Substituent Effects on Di-p-methane and Aza-di-p-methane Rearrangements of Dibenzo[f,h]quinoxalino Barrelenes”, Tetrahedron Lett. 2003, 44, 8761-8764. (SCI: 2.415)(30/57, CHEMISTRY, ORGANIC) Times Cited: 4
  2. Chang, J. Y.*; Hsieh, H. P.; Pan, W. Y.; Liou, J. P.; Bey, S. J.; Chen, L. T.; Song, J. S. “Dual Inhibition of Topoisomerase I and Tubulin Polymerization by BPR0Y007, a Novel Cytotoxic Agent”, Biochem. Pharmacol. 2003, 65, 2009-2019. (SCI: 5.858)(39/276, PHARMACOLOGY & PHARMACY) Times Cited: 22
  3. Hsieh, H. P.*; Liou, J. P.; Lin, Y. T.; Mahindroo, N.; Chang, J. Y.; Yang, Y. N.; Chern, S. S.; Tan, U. K.; Chang, C. W.; Chen, T. W.; Lin, C. H.; Chang, Y. Y.; Wang, C. C. “Structure-Activity and Crystallographic Analysis of Benzophenone Derivatives – the Potential Anticancer Agents”, Bioorg. Med. Chem. Lett. 2003, 13, 101-105. (corresponding author) (SCI: 2.823)(41/62, CHEMISTRY, MEDICINAL) Times Cited: 76

2002

  1. Liou, J. P.; Chang, C. W.; Song, J. S.; Yang, Y. N.; Yeh, C. F.; Tseng, H. Y.; Lo, Y. K.; Chang, Y. L.; Chang, C. M.; Hsieh, H. P* “Synthesis and Structure-Activity Relationship of 2-Aminobenzophenone Derivatives as Antimitotic Agents”, J. Med. Chem. 2002, 45, 2556-2562. (corresponding author) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 127

1990-1999

  1. Hsieh, H. P.; Wu, Y. T.; Chen, S. T.*; Wang, K. T.* “Direct Solid Phase Synthesis of Octreotide Conjugates: Precursors for Use as Tumor-Targeted Radiopharmaceuticals”, Bioorg. Med. Chem. 1999, 7, 1797-1803. (SCI: 2.978) Times Cited: 17
  2. Wu, Y. T.; Hsieh, H. P.; Chen, S. T.*; Wang, K. T.* “Direct Solid Phase Synthesis of Biologically Active Peptide Alcohols”, J. Chin. Chem. Soc. 1999, 46, 135-138. (SCI: 0.718) Times Cited: 3
  3. Hsieh, H. P.; Wu, Y. T.; Wu, C. Y.; Yu, H. M.; Chen, S. T.*; Wang, K. T.* “Facile Solid Phase Synthesis of Octreotide Analogs Using p-Carboxybenzaldehyde as a Novel Linker to Anchor Fmoc-Threoninol to Solid Phase Resins”, Tetrahedron Lett. 1998, 39, 1783-1784. (SCI: 2.618) Times Cited: 11
  4. Hsieh, H. P.; Wu, Y. T.; Chen, S. T.*; Wang, K. T.* “Dihydropyran-2-carboxylic Acid, a New Bifunctional Linker for the Solid Phase Synthesis of Peptides Containing a C-terminal Alcohol”, Chem. Commun. 1998, 649-650. (SCI: 5.787) Times Cited: 11
  5. Hsieh, H. P.; Chen, S. T.*; Wang, K. T.* “Microwave Induced Synthesis of 3,4-Dihydro-2H– pyran-2-carboxaldehyde: A Versatile Linker for Solid Phase Combinatorial Library”, J. Chin, Chem. Soc. 1997, 44, 597-600. (SCI: 0.718) Times Cited: 8
  6. Hsieh, H. P.; McLaughlin, L. W.* “Synthesis of Two C-Nucleosides as “Deletion Modified Analogues of dC and dT”, J. Org. Chem. 1995, 60, 5356-5359. (SCI: 4.002) Times Cited: 40
  7. Hsieh, H. P.; Muller, J. G.; Burrows, C. J.* “Synthesis and DNA Binding Properties of C3-, C12-, and C24-Substituted Amino-Steroids Derived from Bile Acids”, Bioorg. Med. Chem. 1995, 3, 823-838. (SCI: 2.978) Times Cited: 27
  8. Hsieh, H. P.; Muller; J. G.; Burrows, C. J.* “The Effect of Structural Changes in New Steroidal Polyamines on their DNA-Binding Properties”, J. Am. Chem. Soc. 1994, 116, 12077-12078. (SCI: 9.019) Times Cited: 64
  9. Liao, C. C.*; Lin, S. Y.; Hsieh, H. P.; Yang, P. W. “Photochemistry of Quinoxalinobarrelenes and (Benzo[g]quinoxalino)barrelenes”, J. Chin. Chem. Soc. 1992, 39, 275-277. (SCI: 0.718) Times Cited: 7
  10. Liao, C. C.*; Lin, S. Y.; Hsieh, H. P. “Photorearrangement of Some Pyrazinobarrelenes”, Chem. Commun. 1990, 545-547. (SCI: 5.787) Times Cited: 21

Comments are closed.